Recent News

• 03.25.2026 - Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite
• 02.24.2026 - Bio-Techne to Present at Upcoming Investor Conferences
• 02.16.2026 - Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories
• 02.11.2026 - Bio-Techne Announces Changes to its Leadership Team
• 02.04.2026 - 10-Q - Quarterly report [Sections 13 or 15(d)]
• 02.04.2026 - Bio-Techne Declares Dividend
• 02.04.2026 - Bio-Techne Releases Second Quarter Fiscal 2026 Results
• 02.02.2026 - Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative
• 01.28.2026 - Bio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers

Recent Filings

• 03.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2026 - 3 Initial statement of beneficial ownership of securities
• 02.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - 144 Report of proposed sale of securities
• 02.11.2026 - 8-K Current report
• 02.11.2026 - EX-99.1 EX-99.1
• 02.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 02.04.2026 - 8-K Current report
• 02.04.2026 - EX-99.1 EX-99.1